Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery
In clinical trials examining the intraperitoneal (ip) administration of mitoxantrone as therapy of platinum-refractory small-volume residual ovarian cancer, the characteristic "blue color" of the agent has been demonstrated to stain the surface of the peritoneal cavity and to persist for ⩾...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 1993-02, Vol.48 (2), p.185-188 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 188 |
|---|---|
| container_issue | 2 |
| container_start_page | 185 |
| container_title | Gynecologic oncology |
| container_volume | 48 |
| creator | Markman, Maurie Alberts, David Rubin, Stephen Hakes, Thomas Lewis, John L. Reichman, Bonnie Jones, Walter Curtin, John Barakat, Richard Brodar, Franc Peng, Yei-Mei Pennie, Kellie Almadrones, Lois Hoskins, William |
| description | In clinical trials examining the intraperitoneal (ip) administration of mitoxantrone as therapy of platinum-refractory small-volume residual ovarian cancer, the characteristic "blue color" of the agent has been demonstrated to stain the surface of the peritoneal cavity and to persist for ⩾1 month following the last course of therapy. To determine if this blue staining material contains potentially cytotoxic concentrations of mitoxantrone, we analyzed tissue obtained at exploratory laparotomy in six women who had last received the agent administered ip from 6-22 weeks prior to surgery. Concentrations of mitoxantrone ranged from |
| doi_str_mv | 10.1006/gyno.1993.1031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75569997</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825883710310</els_id><sourcerecordid>75569997</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-9599977c60e1aa362ac7b042f94ff85052a6d1065a4c8800a796f3e08373233d3</originalsourceid><addsrcrecordid>eNp1kE1vEzEQhi1EVULhyg1pD4jbpmN77bWPKLRQqag9wNlyvePGaGMH20nJv2eXROXEaTR6n_nQQ8g7CksKIC8fDzEtqdZ8ajl9QRYUtGilEvolWQBoaBUT6hV5XcpPAOBA2Tk5Vx1TUukFWV_tw4DRYeNTbu4xl1Dq3z755luo6beNNaeIzVOo6xCbusYZm5KIdmxWdh_qoblO45ieQnxsbibcbv8Bn3EMe8yHN-TM27Hg21O9ID-ur76vvra3d19uVp9uW8elqq0WWuu-dxKQWssls65_gI553XmvBAhm5UBBCts5pQBsr6XnCIr3nHE-8Avy8bh3m9OvHZZqNqE4HEcbMe2K6YWQ84kJXB5Bl1MpGb3Z5rCx-WAomFmtmdWaWa2Z1U4D70-bdw8bHJ7xk8sp_3DKbXF29NlGF8oz1vWMdd18Vx0xnCzsA2ZTXJiNDyGjq2ZI4X8f_AHMfJXg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75569997</pqid></control><display><type>article</type><title>Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Markman, Maurie ; Alberts, David ; Rubin, Stephen ; Hakes, Thomas ; Lewis, John L. ; Reichman, Bonnie ; Jones, Walter ; Curtin, John ; Barakat, Richard ; Brodar, Franc ; Peng, Yei-Mei ; Pennie, Kellie ; Almadrones, Lois ; Hoskins, William</creator><creatorcontrib>Markman, Maurie ; Alberts, David ; Rubin, Stephen ; Hakes, Thomas ; Lewis, John L. ; Reichman, Bonnie ; Jones, Walter ; Curtin, John ; Barakat, Richard ; Brodar, Franc ; Peng, Yei-Mei ; Pennie, Kellie ; Almadrones, Lois ; Hoskins, William</creatorcontrib><description>In clinical trials examining the intraperitoneal (ip) administration of mitoxantrone as therapy of platinum-refractory small-volume residual ovarian cancer, the characteristic "blue color" of the agent has been demonstrated to stain the surface of the peritoneal cavity and to persist for ⩾1 month following the last course of therapy. To determine if this blue staining material contains potentially cytotoxic concentrations of mitoxantrone, we analyzed tissue obtained at exploratory laparotomy in six women who had last received the agent administered ip from 6-22 weeks prior to surgery. Concentrations of mitoxantrone ranged from <0.1 to 13.8 μg/g of tissue examined. Since any mitoxantrone present on the peritoneal surface will be highly protein bound, any residual drug may not have cytotoxic potential. The dose-response curves of mitoxantrone in a human clonogenic cytotoxicity assay against the RPMI 2780/S human ovarian cell line were virtually identical when the cells were incubated in either 5 or 50% fetal bovine serum, suggesting that protein binding will not significantly impair mitoxantrone-induced tumor cell killing. We conclude that the ip administration of mitoxantrone may lead to prolonged exposure of surface tumor to the high local concentrations of the active cytotoxic agent. This effect may contribute significantly to the antineoplastic potential of ip mitoxantrone in patients with small-volume residual ovarian cancer.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1006/gyno.1993.1031</identifier><identifier>PMID: 8428689</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Chemotherapy ; Dose-Response Relationship, Drug ; Female ; Humans ; Injections, Intraperitoneal ; Medical sciences ; Mitoxantrone - administration & dosage ; Mitoxantrone - analysis ; Ovarian Neoplasms - drug therapy ; Peritoneal Cavity ; Pharmacology. Drug treatments ; Tumor Cells, Cultured</subject><ispartof>Gynecologic oncology, 1993-02, Vol.48 (2), p.185-188</ispartof><rights>1993 Academic Press</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-9599977c60e1aa362ac7b042f94ff85052a6d1065a4c8800a796f3e08373233d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090825883710310$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4722447$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8428689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Markman, Maurie</creatorcontrib><creatorcontrib>Alberts, David</creatorcontrib><creatorcontrib>Rubin, Stephen</creatorcontrib><creatorcontrib>Hakes, Thomas</creatorcontrib><creatorcontrib>Lewis, John L.</creatorcontrib><creatorcontrib>Reichman, Bonnie</creatorcontrib><creatorcontrib>Jones, Walter</creatorcontrib><creatorcontrib>Curtin, John</creatorcontrib><creatorcontrib>Barakat, Richard</creatorcontrib><creatorcontrib>Brodar, Franc</creatorcontrib><creatorcontrib>Peng, Yei-Mei</creatorcontrib><creatorcontrib>Pennie, Kellie</creatorcontrib><creatorcontrib>Almadrones, Lois</creatorcontrib><creatorcontrib>Hoskins, William</creatorcontrib><title>Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>In clinical trials examining the intraperitoneal (ip) administration of mitoxantrone as therapy of platinum-refractory small-volume residual ovarian cancer, the characteristic "blue color" of the agent has been demonstrated to stain the surface of the peritoneal cavity and to persist for ⩾1 month following the last course of therapy. To determine if this blue staining material contains potentially cytotoxic concentrations of mitoxantrone, we analyzed tissue obtained at exploratory laparotomy in six women who had last received the agent administered ip from 6-22 weeks prior to surgery. Concentrations of mitoxantrone ranged from <0.1 to 13.8 μg/g of tissue examined. Since any mitoxantrone present on the peritoneal surface will be highly protein bound, any residual drug may not have cytotoxic potential. The dose-response curves of mitoxantrone in a human clonogenic cytotoxicity assay against the RPMI 2780/S human ovarian cell line were virtually identical when the cells were incubated in either 5 or 50% fetal bovine serum, suggesting that protein binding will not significantly impair mitoxantrone-induced tumor cell killing. We conclude that the ip administration of mitoxantrone may lead to prolonged exposure of surface tumor to the high local concentrations of the active cytotoxic agent. This effect may contribute significantly to the antineoplastic potential of ip mitoxantrone in patients with small-volume residual ovarian cancer.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intraperitoneal</subject><subject>Medical sciences</subject><subject>Mitoxantrone - administration & dosage</subject><subject>Mitoxantrone - analysis</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Peritoneal Cavity</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumor Cells, Cultured</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1vEzEQhi1EVULhyg1pD4jbpmN77bWPKLRQqag9wNlyvePGaGMH20nJv2eXROXEaTR6n_nQQ8g7CksKIC8fDzEtqdZ8ajl9QRYUtGilEvolWQBoaBUT6hV5XcpPAOBA2Tk5Vx1TUukFWV_tw4DRYeNTbu4xl1Dq3z755luo6beNNaeIzVOo6xCbusYZm5KIdmxWdh_qoblO45ieQnxsbibcbv8Bn3EMe8yHN-TM27Hg21O9ID-ur76vvra3d19uVp9uW8elqq0WWuu-dxKQWssls65_gI553XmvBAhm5UBBCts5pQBsr6XnCIr3nHE-8Avy8bh3m9OvHZZqNqE4HEcbMe2K6YWQ84kJXB5Bl1MpGb3Z5rCx-WAomFmtmdWaWa2Z1U4D70-bdw8bHJ7xk8sp_3DKbXF29NlGF8oz1vWMdd18Vx0xnCzsA2ZTXJiNDyGjq2ZI4X8f_AHMfJXg</recordid><startdate>19930201</startdate><enddate>19930201</enddate><creator>Markman, Maurie</creator><creator>Alberts, David</creator><creator>Rubin, Stephen</creator><creator>Hakes, Thomas</creator><creator>Lewis, John L.</creator><creator>Reichman, Bonnie</creator><creator>Jones, Walter</creator><creator>Curtin, John</creator><creator>Barakat, Richard</creator><creator>Brodar, Franc</creator><creator>Peng, Yei-Mei</creator><creator>Pennie, Kellie</creator><creator>Almadrones, Lois</creator><creator>Hoskins, William</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930201</creationdate><title>Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery</title><author>Markman, Maurie ; Alberts, David ; Rubin, Stephen ; Hakes, Thomas ; Lewis, John L. ; Reichman, Bonnie ; Jones, Walter ; Curtin, John ; Barakat, Richard ; Brodar, Franc ; Peng, Yei-Mei ; Pennie, Kellie ; Almadrones, Lois ; Hoskins, William</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-9599977c60e1aa362ac7b042f94ff85052a6d1065a4c8800a796f3e08373233d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intraperitoneal</topic><topic>Medical sciences</topic><topic>Mitoxantrone - administration & dosage</topic><topic>Mitoxantrone - analysis</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Peritoneal Cavity</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Markman, Maurie</creatorcontrib><creatorcontrib>Alberts, David</creatorcontrib><creatorcontrib>Rubin, Stephen</creatorcontrib><creatorcontrib>Hakes, Thomas</creatorcontrib><creatorcontrib>Lewis, John L.</creatorcontrib><creatorcontrib>Reichman, Bonnie</creatorcontrib><creatorcontrib>Jones, Walter</creatorcontrib><creatorcontrib>Curtin, John</creatorcontrib><creatorcontrib>Barakat, Richard</creatorcontrib><creatorcontrib>Brodar, Franc</creatorcontrib><creatorcontrib>Peng, Yei-Mei</creatorcontrib><creatorcontrib>Pennie, Kellie</creatorcontrib><creatorcontrib>Almadrones, Lois</creatorcontrib><creatorcontrib>Hoskins, William</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Markman, Maurie</au><au>Alberts, David</au><au>Rubin, Stephen</au><au>Hakes, Thomas</au><au>Lewis, John L.</au><au>Reichman, Bonnie</au><au>Jones, Walter</au><au>Curtin, John</au><au>Barakat, Richard</au><au>Brodar, Franc</au><au>Peng, Yei-Mei</au><au>Pennie, Kellie</au><au>Almadrones, Lois</au><au>Hoskins, William</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>1993-02-01</date><risdate>1993</risdate><volume>48</volume><issue>2</issue><spage>185</spage><epage>188</epage><pages>185-188</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>In clinical trials examining the intraperitoneal (ip) administration of mitoxantrone as therapy of platinum-refractory small-volume residual ovarian cancer, the characteristic "blue color" of the agent has been demonstrated to stain the surface of the peritoneal cavity and to persist for ⩾1 month following the last course of therapy. To determine if this blue staining material contains potentially cytotoxic concentrations of mitoxantrone, we analyzed tissue obtained at exploratory laparotomy in six women who had last received the agent administered ip from 6-22 weeks prior to surgery. Concentrations of mitoxantrone ranged from <0.1 to 13.8 μg/g of tissue examined. Since any mitoxantrone present on the peritoneal surface will be highly protein bound, any residual drug may not have cytotoxic potential. The dose-response curves of mitoxantrone in a human clonogenic cytotoxicity assay against the RPMI 2780/S human ovarian cell line were virtually identical when the cells were incubated in either 5 or 50% fetal bovine serum, suggesting that protein binding will not significantly impair mitoxantrone-induced tumor cell killing. We conclude that the ip administration of mitoxantrone may lead to prolonged exposure of surface tumor to the high local concentrations of the active cytotoxic agent. This effect may contribute significantly to the antineoplastic potential of ip mitoxantrone in patients with small-volume residual ovarian cancer.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>8428689</pmid><doi>10.1006/gyno.1993.1031</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 1993-02, Vol.48 (2), p.185-188 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75569997 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antineoplastic agents Biological and medical sciences Chemotherapy Dose-Response Relationship, Drug Female Humans Injections, Intraperitoneal Medical sciences Mitoxantrone - administration & dosage Mitoxantrone - analysis Ovarian Neoplasms - drug therapy Peritoneal Cavity Pharmacology. Drug treatments Tumor Cells, Cultured |
| title | Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T10%3A21%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20for%20Persistence%20of%20Mitoxantrone%20within%20the%20Peritoneal%20Cavity%20Following%20Intraperitoneal%20Delivery&rft.jtitle=Gynecologic%20oncology&rft.au=Markman,%20Maurie&rft.date=1993-02-01&rft.volume=48&rft.issue=2&rft.spage=185&rft.epage=188&rft.pages=185-188&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1006/gyno.1993.1031&rft_dat=%3Cproquest_cross%3E75569997%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75569997&rft_id=info:pmid/8428689&rft_els_id=S0090825883710310&rfr_iscdi=true |